A group of international experts responded to the publication of the recent Systemic Synuclein Sampling Study (S4), which found alpha-synuclein to be a specific—but not sensitive—marker of Parkinson’s disease. Their letter details how the study’s methods, rather than the specificity of alpha-synuclein as a marker for Parkinson’s disease, may have produced the results.
Drs. Christopher Gibbons and Roy Freeman–two of the founders of CND Life Sciences who also serve as senior medical advisors–recently had their research on orthostatic hypotension as an early sign of Parkinson’s disease and dementia highlighted in a New York Times article.
CND will use its novel cutaneous neurodiagnostics platform to detect and measure changes in TDP-43 in patients treated with edaravone
Company launches the Syn-One Test™ as the first commercially available skin-based test to help physicians confirm diagnosis of Parkinson’s disease and other neurodegenerative disorders